Search - tctmd.com

Displaying 61 - 80 of 114

Sort: Relevancy | Date

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

Podcast TCTMD Talking Points

Episode 29: ILLUMENATE US: A Paclitaxel-Coated Balloon vs an Uncoated Balloon for Diseased Superficial Femoral and Popliteal Arteries

September 06, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

L.A. McKeown

September 20, 2016

News Daily News

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Todd Neale

September 13, 2016

News Daily News

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

Todd Neale

April 28, 2016

News Industry News

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

April 07, 2016

News Industry News

Boston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial

February 21, 2016

Advertisement

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Episode 29: ILLUMENATE US: A Paclitaxel-Coated Balloon vs an Uncoated Balloon for Diseased Superficial Femoral and Popliteal Arteries

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

Drug-Coated Balloon Gets Expanded Indication for In-Stent Restenosis in PAD

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

Boston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content